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Abstract
Introduction—Hypertension and diabetes, both independent risk factors for cardiovascular 
disease, often coexist. The hypertension-increased medical expenditures by diabetes status is 
unclear, however. This study estimated annual total medical expenditures in U.S. adults by 
hypertension and diabetes status.
Methods—The study population consisted of 40,746 civilian, non-institutionalized adults aged 
≥18 years who participated in the 2013 or 2014 Medical Expenditure Panel Survey. The authors 
separately estimated hypertension-increased medical expenditures using two-part econometric and 
generalized linear models for the total; diabetes (n=4,396); and non-diabetes (n=36,250) 
populations and adjusted the results into 2014 U.S. dollars. Data were analyzed in 2017 and 
estimated the hypertension-increased medical expenditures by type of medical service and 
payment source.
Results—The prevalence of hypertension was 34.9%, 78.3%, and 30.1% for the total, diabetes, 
and non-diabetes populations, respectively. The respective mean unadjusted annual per capita 
medical expenditures were $5,225, $12,715, and $4,390. After controlling for potential 
confounders, hypertension-increased expenditures were $2,565, $4,434, and $2,276 for total, 
diabetes, and non-diabetes populations, respectively (all p<0.001). The hypertension-increased 
expenditure was highest for inpatient stays among the diabetes population ($1,730, p<0.001), and 
highest for medication among the non-diabetes population ($687, p<0.001). By payment source, 
Medicare ranked first in hypertension-increased expenditures for the diabetes ($2,753) and second 
for the non-diabetes ($669) populations (both p<0.001).
Conclusions—Hypertension-increased medical expenditures were substantial and varied by 
medical service type and payment sources. These findings may be useful as inputs for cost-
effectiveness evaluations of hypertension interventions by diabetes status.
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Introduction
In 2013–2014 the overall prevalence of hypertension among American adults aged ≥18 years 
was 29.3% (75.2 million people).1,2 From 1980 to 2014, the number of people in the U.S. 
civilian, non-institutionalized population with diagnosed diabetes more than tripled, from 
5.5 million to 21.9 million, and the rate of diagnosed diabetes increased among people of all 
age groups.3,4 Both hypertension and diabetes are serious health problems requiring timely 
medical treatment, and they are also major risk factors for cardiovascular disease (CVD), the 
leading cause of death in the U.S.5 In addition, many studies have demonstrated the 
tremendous economic burden associated with hypertension, diabetes, and CVD.6–13 The 
health and economic burdens associated with hypertension, diabetes, and CVD suggest a 
pressing need to develop effective public health strategies to prevent and control these 
common health conditions.
Hypertension and diabetes often coexist.14–20 For example, the prevalence of hypertension 
among people with diabetes has been estimated at more than 70%,20 and the 2013–2014 
Medical Expenditure Survey (MEPS) in the U.S. showed that this prevalence could be as 
high as 78%. The coexistence of hypertension and diabetes can markedly increase further an 
affected person's risk of CVD, 19 and thus comprehensive interventions, such as the use of 
various strategies to control hypertension among patients with diabetes are needed for 
dealing with these costly health conditions. Information on economic costs by hypertension 
and diabetes status should be useful in evaluating intervention programs.
The influence of hypertension on total medical expenditures by diabetes status is unclear, 
even though some studies have used hypertension as a risk factor for the economic burden of 
diabetes.9–13 To the authors' knowledge, studies have not compared hypertension-induced 
medical expenditures between populations with and without diabetes. The present study 
estimates hypertension-increased expenditures by type of medical service (inpatient, 
outpatient, prescription medications, emergency room, and other medical services) and 
payment source (Medicare, Medicaid, private insurance, out of pocket, other public 
programs, and other sources) for adults with and without diabetes in the U.S.
Methods
Study Sample
This study used the most recent comprehensive nationally representative survey of health 
status, use of health care, medical expenditures, payment sources, and health insurance 
coverage for the U.S. civilian non-institutionalized population, the MEPS. Data were pooled 
from the 2013 and 2014 MEPSs to increase the sample size for the population with 
hypertension and diabetes. The MEPS is sponsored by the U.S. Agency for Healthcare 
Research and Quality and the Centers for Disease Control and Prevention. Respondents to 
the MEPS are drawn annually from a subsample of households that participated in the 
immediately preceding National Health Interview Survey, which is administered by the 
National Center for Health Statistics of the Centers for Disease Control and Prevention. 
Each year, the MEPS samples about 39,000 individuals from the National Health Interview 
Survey. From the full-year consolidated data file for the 2013 and 2014 MEPSs, the authors 
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identified 40,746 adult men and non-pregnant women aged ≥18 years for the analyses 
(excluded pregnant women, n=1,297). Detailed descriptions of the MEPS survey design, 
sample design, and methods used to minimize sources of non-sampling errors have been 
published elsewhere.21,22 The MEPS has been used extensively for research on various 
health economics topics, including the economic burden of hypertension, diabetes, and 
CVD.6,9,23–30
Information on medical expenditures was obtained from household interviews, with the data 
obtained subsequently confirmed through physician's offices, hospitals, and records of 
insurance coverage based on actual payment. Expenditures were categorized into five 
service types: inpatient, outpatient, emergency room visit, prescription medications, and 
other medical services, such as medical equipment for home health care and other 
miscellaneous items or services. By payment sources, the expenditures were grouped into 
Medicare, out of pocket, private insurance, Medicaid, and other sources such as Veterans 
Administration, other public and unclassified sources. All expenditures of 2013 were 
adjusted to 2014 U.S. dollars using the gross domestic product deflator.31 In addition to the 
detailed information on expenditures by service types and payment sources, the MEPS 
contained a variety of socioeconomic variables and health risk factors that can be controlled 
for in regression analysis (Appendix Table 1, available online).
Measures
Hypertension was defined as ever having been diagnosed as having high blood pressure 
other than during pregnancy. Diabetes was defined as ever having been diagnosed with 
diabetes excluding gestational diabetes. With the MEPS, there are two ways to identify 
certain health conditions, such as hypertension and diabetes. One uses the full-year 
consolidated files to identify persons who ever had a health condition, and another uses 
ICD-9 diagnosis codes in the medical condition files to identify persons who used any 
medical services related to that condition during the survey period. The first method was 
used to define hypertension and diabetes to be consistent with those used in the literature.
4,26,29,30
Statistical Analysis
The authors compared medical expenditures between hypertensive and normotensive adults 
for the total, diabetes, and non-diabetes populations separately. Because of the nature of the 
MEPS medical expenditure data (e.g., zero expenditures for some respondents and 
skewness), a two-part econometric model and generalized linear model (GLM) were 
employed for estimating the medical expenditures associated with hypertension for the three 
study samples (total, with diabetes, no diabetes). These approaches have frequently been 
used by researchers in studying information on medical costs.23,26,29 For the situation with a 
significant number of zero expenditures, the authors used a two-part model consisting of a 
logit model to estimate the probability of an individual having had any medical expenditures 
and a GLM for the individuals with positive medical expenditures with a log link to estimate 
the amount of medical expenditure associated with hypertension. Finally, based on the two-
part regression results, hypertension-increased expenditure for the total, diabetes, and no-
diabetes populations were derived separately. For those with a small number of zero medical 
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expenditures, GLM with a log link and gamma distribution was used for estimating 
hypertension-increased medical expenditures. Specifically, the regression results were used 
to predict the mean annual expenditures for people with hypertension and those without. For 
each individual the expenditure was predicted twice, once by assuming this person had 
hypertension and another by assuming this person had normal blood pressure. The 
difference between the two predicted annual mean expenditures was the hypertension-
increased expenditure. That is, the hypertension-increased expenditure is calculated as the 
incremental expenditure comparing people with hypertension and those without, rather than 
as hypertension treatment expenditures. For each study sample (total, with diabetes, no 
diabetes), the authors ran the same two-part model or GLM to estimate hypertension-
increased expenditures by five service types and five payment sources, respectively. There 
was no further subpopulation analysis.
The regression analyses included age, sex, race/ethnicity, marital status, education, 
geographic region, family income, insurance status, smoking status, body weight, and 
perceived general health status as the main control variables. For analyzing medical 
expenditures, some major comorbidities or a comorbidity index, such as the Charlson 
comorbidity index, should be controlled. However, hypertension is a health condition as well 
as an independent risk factor for many chronic diseases, including heart disease and stroke. 
Controlling major comorbidities or Charlson comorbidity index will potentially 
underestimate the expenditure that is associated with hypertension.23,26 The authors believe 
that for this analysis on the general population including smoking, body weight, and self-
reported health status are sufficient for estimating the total medical expenditures. Data were 
analyzed in 2017, and Stata, version 14, was used for all the analyses.
Results
The prevalence of hypertension was 34.9% in the general population, 78.3% for persons 
with diabetes, and 30.1% for people without diabetes (Table 1). Prevalence increased sharply 
with age in all three groups, with a particularly high prevalence (all above 54%) seen in the 
diabetes population even in the youngest age group (18– 44 years). Overall, prevalence was 
slightly higher for men than for women. By race/ethnicity, non-Hispanic blacks had the 
highest prevalence, reaching 83.5% for blacks with diabetes. People with obesity had a 
much higher prevalence of hypertension than people of normal weight, at 82.5% for people 
with obesity and diabetes.
The mean unadjusted annual medical expenditure for the general population was $5,225 
(SE=102), and hypertensive persons had more than twice the expenditure of normotensives 
($8,854 [SE=210] vs $3,276 [SE=93]; Table 2). In the diabetes population, the estimate for 
those with hypertension was $13,929 (SE=541). In general, expenditures increased sharply 
with age, but even at a young age (18–44 years) they were high for people with both diabetes 
and hypertension ($9,943 [SE=1,317]). Medical expenditures were higher for men than for 
women for people with diabetes, but higher for women than men for those without diabetes. 
Overall, non-Hispanic whites and blacks had higher expenditures than Hispanics, and such 
differences were seen throughout the populations without diabetes and in most cases in the 
population with that disorder. The patterns of higher expenditures for hypertensive versus 
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normotensive persons were for the most part similar across various population groups as 
well as across service types and payment sources, and the majority of the differences were 
statistically significant.
The mean adjusted annual medical expenditure associated with hypertension was estimated 
at $2,565 for the overall study sample, $4,434 for the population with diabetes, and $2,276 
for those without diabetes (all p<0.001). By service type, in the overall study population, the 
hypertension-increased expenditure was highest for inpatient care ($767), followed by 
prescription medication ($758) and outpatient services ($595, all p<0.001 vs those who were 
normotensive; Table 3). In the population with diabetes, the hypertension-increased 
expenditure was highest for inpatient care ($1,730), followed by medication ($1,272) and 
outpatient services ($926, all p<0.001). In the population without diabetes, the hypertension-
increased expenditure was highest for prescription medication ($687), followed by 
outpatient services ($565) and inpatient care ($468, all p<0.001).
By payment source, for the total population, hypertension-increased expenditure was paid 
most often by the Medicare program ($1,159), followed by private insurance ($736) and 
other sources ($254, all p<0.001 vs those who were normotensive; Table 3). Increased 
Medicare payment again ranked first for the population with diabetes ($2,753), followed by 
private insurance ($1,346) and out of pocket ($395, all p<0.001). For the population without 
diabetes, the hypertension-increased expenditures paid by private insurance were $716, 
followed by Medicare ($669) and Medicaid ($312). It is worth noting that for the population 
without diabetes, although private insurance payment ranked first, at $716, Medicare 
payment was also high, accounting for nearly one third of the total expenditures ($669 of 
$2,276).
Discussion
These results confirmed that hypertension is a high-prevalence condition in the U.S. About 
one third of U.S. adults had this condition in 2013–2014, similar to the rate of 32.2% from 
the 2007 MEPS.26 And these results further suggest an alarmingly high prevalence of 
hypertension in the diabetes population of 78%. The latter figure is consistent with the 
findings from a report on the economic costs of diabetes in the U.S.20 The coexistence of 
hypertension and diabetes presents a formidable public health challenge that underscores the 
need for developing comprehensive intervention programs focusing on both health 
conditions. For adults with diabetes, aggressive treatment of hypertension is recommended.
32
 Clearly, hypertension prevention should be a public health priority, especially among 
people with diabetes.
The current results for medical expenditure by hypertension and diabetes status provide 
much needed information that indicates the great economic burden associated with these 
health conditions. Based on the national weighted number of persons with diabetes and 
hypertension (16.16 million) and this study's estimated mean annual hypertension-increased 
medical expenditures of $4,434, the national burden of hypertension among people with 
diabetes was estimated at $71.6 billion in 2013–2014. Similarly, the national burden of 
hypertension among people without diabetes was estimated at $126.7 billion. Thus, the total 
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national burden of hypertension could be as high as $198.3 billion in 2014 U.S. dollars. 
Although not directly comparable, high medical expenditures associated with hypertension 
have been reported in the literature. Using 1998 MEPS data, Graden30 estimated the total 
direct medical expenditures for people with self-reported hypertension at $173 billion. 
Another study using a variety of data sets reported healthcare spending attributable to 
hypertension at $108.8 billion in 1998.33
Hypertension-associated medical expenditures were substantial and higher in persons with 
diabetes than those without. By type of medical service utilization, the population with 
diabetes incurred much higher spending for inpatient services and prescription medications 
than for outpatient services, contrasting sharply with the population without diabetes, where 
the costs of prescription medication were the highest at $687, but close with the costs of 
outpatient and inpatient services in size ($565 and $468). More important, the estimate for 
inpatient care for those with diabetes ($1,730) was 3.7 times as high as it was for the 
population without diabetes ($468).
These findings have implications for the development of interventions and program 
evaluations. For example, focusing on investigating the use of inpatient services and 
prescription medications is the key to controlling the medical expenditures of the population 
with diabetes, whereas for the population without diabetes, prescription medication and 
outpatient services should be the focal point for controlling medical expenditures. For both 
populations with and without diabetes, hypertension-increased expenditures are mainly 
because of medications. The literature has shown that prescription medications accounted 
for 430% of the total medical expenditures in diabetes and 25% in non-diabetes populations.
29
 Furthermore, expenditures on medications increased by more than three times from 1987 
to 2011 in persons with diabetes. The substantial hypertension-associated expenditures 
overall and in prescription medications, plus the high prevalence of hypertension, imply that 
hypertension imposes a large financial burden on the healthcare system and further 
underscores the need for hypertension prevention.
By source of payment, this study found that Medicare was the most important source, 
especially for the population with diabetes, higher than any other payment sources for 
hypertension-increased medical expenditures. This finding suggests the need to manage 
hypertension better among the population with diabetes, as doing so would appear to have 
great potential for alleviating the economic burden on public insurance programs. Programs 
for improving the quality of care, such as incorporating hypertension management in the 
care of the population with diabetes and aggressive hypertension treatment among diabetes 
populations, might be viable economically.32,34
Several strengths of this study are worth noting. First, data are from the most recent 
comprehensive national survey, MEPS, which not only provides nationally representative 
information regarding the patterns of healthcare utilization in the U.S. but also yields high-
quality data on medical expenditures. The medical expenditures were based on payments 
rather than charges and were obtained by face-to-face interviews and confirmed by 
healthcare providers and insurance plans. Having high-quality expenditure data and a large, 
nationally representative sample were critical in developing scientifically sound estimates of 
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hypertension-increased medical expenditures. Second, a two-part econometric model was 
used, which was plausible for analyzing medical expenditures developed using a survey of 
the general population, where there are many people who incur no medical expenditures at 
all in a given year and where such data are often skewed. Additionally, the MEPS contained 
various demographic and socioeconomic variables that were used as controls in the 
regression models.
Third, the authors not only analyzed hypertension-associated medical expenditures by 
diabetes status but also investigated expenditures by types of medical service. These 
explorations provided detailed information on expenditures by hypertension and diabetes 
status. These detailed presentations of expenditures should be useful in developing various 
interventions for managing hypertension and diabetes among various targeted populations. 
Finally, the use of five payment sources enabled the authors to derive the burden for public 
programs, such as Medicare and Medicaid. This study found that Medicare ranked first for 
hypertension-increased medical expenditures among the population with diabetes.
Limitations
Its considerable strengths notwithstanding, two limitations associated with this study should 
be considered when interpreting these results. First, although the MEPS is the largest 
nationally representative survey in the U.S. monitoring national health status, healthcare 
utilization, and medical spending, the survey population was limited to non-institutionalized, 
civilian men and women. Because rates of both hypertension and diabetes are closely related 
with aging, and aging populations are more likely to reside in nursing homes or other 
institutions that the MEPS does not cover, these estimates should be interpreted as 
conservative. Second, although the MEPS has been a panel survey since 1996 and the 2013 
and 2014 MEPS data were pooled for this analysis, the nature of the survey and analytic 
sample still allow only a cross-sectional analysis. Thus, no causal relationship should be 
assumed.
Conclusions
The authors succeeded in conducting a comprehensive analysis of hypertension-increased 
medical expenditures by employing an advanced econometric modeling technique using a 
large nationally representative survey. The results indicate that hypertension increases 
medical expenditures substantially, especially among the diabetes population. This study 
found that in the general population the increased expenditure was similar for the use of 
inpatient services, prescription medication, and outpatient services, but in the population 
with diabetes the use of inpatient services and prescription medication ranked first and 
second and sizably higher than for any other particular service type. A large proportion of 
the higher expenditure due to hypertension was financed by Medicare programs, again 
particularly in the population with diabetes. These findings suggest that interventions to 
reduce the impact of hypertension in the population with diabetes may be economically 
viable because they can potentially control medical expenditures, especially alleviating the 
burden on Medicare programs.
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Table 1
Prevalence of Hypertensiona (Weighted % [SE]) in U.S. Adults, 2013–2014 Medical 
Expenditure Panel Survey
Variables Overall (N=40,746; weighted 
n=205,490,266)
With diabetes (n=4,496; 
weighted n=20,623,245)
Without diabetes (n=36,250; 
weighted n=184,867,021) p-value
d
Total 34.94 (0.45) 78.33 (1.00) 30.10 (0.44) <0.001
Age, years <0.001
 18–44 13.81 (0.39) 54.87 (3.07) 12.78 (0.40)
 45–64 42.09 (0.73) 75.83 (1.55) 37.38 (0.75)
 >65 69.60 (0.8830) 86.30 (1.15) 64.57 (1.06)
Sex 0.009
 Male 36.49 (0.59) 79.50 (1.34) 31.76 (0.63)
 Female 33.44 (0.62) 77.23 (1.46) 28.48 (0.61)
Race/ethnicity <0.001
 Non-Hispanic white 36.63 (0.60) 79.85 (1.33) 32.14 (0.59)
 Non-Hispanic black 42.82 (0.83) 83.50 (1.87) 36.95 (0.86)
 Hispanic 25.48 (0.68) 71.69 (1.42) 20.12 (0.63)
 Other race 26.76 (1.13) 70.40 (3.19) 21.39 (1.07)
Married <0.001
 Yes 37.42 (0.62) 76.88 (1.45) 32.60 (0.62)
 No 32.25 (0.68) 80.22 (1.40) 27.44 (0.66)
Education <0.001
 Less than high school 37.81 (0.93) 81.22 (1.66) 30.49 (1.01)
 High school graduate 40.84 (0.83) 81.43 (1.66) 35.15 (0.85)
 More than high school 31.73 (0.54) 75.13 (1.61) 27.92 (0.51)
Geographic region <0.001
 Northeast 33.03 (1.09) 73.80 (2.51) 28.61 (1.06)
 Midwest 35.08 (0.96) 80.78 (2.37) 30.06 (0.91)
 South 38.49 (0.75) 81.30 (1.45) 33.20 (0.74)
 West 30.59 (0.93) 73.67 (2.09) 26.42 (0.91)
Family incomeb <0.001
 Low 37.86 (0.68) 80.28 (1.42) 31.77 (0.71)
 Middle 33.97 (0.73) 78.28 (1.67) 29.03 (0.73)
 High 33.49 (0.61) 76.18 (1.76) 29.69 (0.61)
Any health insurance <0.001
 Yes 36.99 (0.50) 78.82 (1.06) 31.93 (0.48)
 No 21.44 (0.77) 71.60 (3.23) 18.74 (0.71)
Current smoker <0.001
 Yes 36.66 (1.08) 71.52 (3.34) 33.39 (1.06)
 No 34.61 (0.49) 79.42 (1.02) 29.46 (0.49)
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Variables Overall (N=40,746; weighted 
n=205,490,266)
With diabetes (n=4,496; 
weighted n=20,623,245)
Without diabetes (n=36,250; 
weighted n=184,867,021) p-value
d
Body weightc
 Normal 20.91 (0.63) 65.69 (2.59) 19.05 (0.586) <0.001
 Overweight 35.63 (0.69) 76.72 (1.63) 31.44 (0.72)
 Obese 49.93 (0.72) 82.46 (1.34) 42.93 (0.76)
Self-rated health status <0.001
 Excellent 16.37 (0.63) 68.55 (4.52) 15.18 (0.63)
 Very good 31.00 (0.6510) 71.19 (2.19) 28.38 (0.66)
 Good 44.2 (0.69) 79.07 (1.51) 38.70 (0.72)
 Fair or poor 61.47 (0.95) 83.22 (1.45) 53.14 (1.11)
a
Hypertension was identified by participants' response to “whether the person had ever been diagnosed as having high blood pressure other than 
during pregnancy.” Diabetes was identified by participants' response to “whether the person had ever been diagnosed with diabetes excluding 
gestational diabetes.”
b
For family income variable, low=family income <200% of poverty line; middle=family income 200%-400% of poverty line; high=family income 
4400% of poverty line.
c
For body weight variable, normal=BMI (defined as weight in kilograms divided by height in meters squared) <25; overweight=BMI 25-30; 
obese=BMI 430.
dChi-square test was used to test the distribution difference of categories between individuals with and without diabetes.
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Table 3
Estimated Hypertension-Increased Annual Total Medical Expenditure (95% CI) (2014 $) 
for U.S. Adults by Diabetes Status, a 2013–2014 Medical Expenditure Panel Survey
Categories Total population (N=40,746) Population with diabetes 
(n=4,496)
Population without diabetes 
(n=36,250)
p-value for diabetes 
vs no diabetes
Totalb 2,565 (2521, 2609) 4,434 (4329, 4538) 2,276 (2237, 2315) <0.001
Service type
 Inpatient 767 (745, 788) 1,730 (1671, 1788) 468 (457, 480) <0.001
 Outpatient 595 (587, 602) 926 (902, 951) 565 (558, 572) <0.001
 Medication 758 (747, 769) 1,272 (1243, 1301) 687 (677, 697) <0.001
 Emergency room 82 (80, 84) 179 (175, 183) 59 (58, 60) <0.001
 Others 233 (229, 237) 363 (351, 375) 218 (214, 222) <0.001
Payment source
 Medicare 1,159 (1117, 1201) 2,753 (2655, 2852) 669 (646, 692) <0.001
 Out-of-pocket 220 (218, 223) 395 (385, 406) 182 (180, 184) <0.001
 Private insurance 736 (719, 754) 1,346 (1283, 1408) 716 (698, 734) <0.001
 Medicaid 197 (183, 211) 317 (296, 337) 312 (293, 332) 0.608
 Others 254 (251, 258) 226 (219, 232) 277 (273, 282) <0.001
a
Regression estimation for total expenditure, expenditure for outpatient service and prescription medication, and payment source of out-of-pocket 
for population with diabetes used a generalized linear model (GLM) with log link and gamma distribution because of the small number of zero 
expenditures. All other estimations used a two-part model.
b
Total does not equal to the sum of service types or sum of payment sources because of separate regression estimates.
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